Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Earendil Labs, an expert in AI-driven research and development of next-generation biologics therapeutics, and Sanofi have ...

Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody, nirsevimab, in a prefilled injection used ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a Phase II trial. Preliminary ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Earendil Labs and Sanofi today announced that they have entered into a license agreement for two potential first-in-class ...

MIDDLETOWN, Del., April 17, 2025 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that ...

MIDDLETOWN, Del., April 17, 2025 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that ...